Raymond James Financial Services Advisors Inc. Sells 12,361 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL)

Raymond James Financial Services Advisors Inc. lessened its stake in Ocular Therapeutix, Inc. (NASDAQ:OCUL) by 16.6% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 62,040 shares of the biopharmaceutical company’s stock after selling 12,361 shares during the period. Raymond James Financial Services Advisors Inc.’s holdings in Ocular Therapeutix were worth $277,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in the stock. Barclays PLC boosted its position in shares of Ocular Therapeutix by 22.9% during the 3rd quarter. Barclays PLC now owns 25,963 shares of the biopharmaceutical company’s stock valued at $81,000 after purchasing an additional 4,840 shares in the last quarter. SG Americas Securities LLC boosted its position in shares of Ocular Therapeutix by 60.5% during the 4th quarter. SG Americas Securities LLC now owns 19,646 shares of the biopharmaceutical company’s stock valued at $88,000 after purchasing an additional 7,404 shares in the last quarter. Raymond James & Associates boosted its position in shares of Ocular Therapeutix by 7.0% during the 4th quarter. Raymond James & Associates now owns 129,012 shares of the biopharmaceutical company’s stock valued at $575,000 after purchasing an additional 8,451 shares in the last quarter. Profund Advisors LLC boosted its position in shares of Ocular Therapeutix by 94.1% during the 3rd quarter. Profund Advisors LLC now owns 20,827 shares of the biopharmaceutical company’s stock valued at $65,000 after purchasing an additional 10,099 shares in the last quarter. Finally, Rafferty Asset Management LLC bought a new stake in shares of Ocular Therapeutix during the 3rd quarter valued at about $37,000. Institutional investors own 59.21% of the company’s stock.

Ocular Therapeutix Stock Down 2.8 %

OCUL stock opened at $5.08 on Tuesday. The stock’s 50 day simple moving average is $8.73 and its 200 day simple moving average is $5.36. Ocular Therapeutix, Inc. has a fifty-two week low of $2.00 and a fifty-two week high of $11.31. The company has a debt-to-equity ratio of 0.82, a quick ratio of 6.59 and a current ratio of 6.66. The company has a market cap of $754.30 million, a P/E ratio of -4.06 and a beta of 1.31.

Ocular Therapeutix (NASDAQ:OCUL) last issued its quarterly earnings data on Monday, March 11th. The biopharmaceutical company reported ($0.28) EPS for the quarter, hitting the consensus estimate of ($0.28). The firm had revenue of $14.80 million during the quarter, compared to the consensus estimate of $15.31 million. Ocular Therapeutix had a negative return on equity of 321.12% and a negative net margin of 138.15%. On average, research analysts expect that Ocular Therapeutix, Inc. will post -0.68 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

OCUL has been the topic of several research analyst reports. JMP Securities restated a “market outperform” rating and set a $24.00 target price on shares of Ocular Therapeutix in a research report on Tuesday, April 16th. HC Wainwright restated a “buy” rating and set a $16.00 target price on shares of Ocular Therapeutix in a research report on Friday. Piper Sandler upped their price target on Ocular Therapeutix from $10.00 to $15.00 and gave the stock an “overweight” rating in a research note on Monday, February 26th. StockNews.com downgraded Ocular Therapeutix from a “hold” rating to a “sell” rating in a research note on Friday, April 5th. Finally, Bank of America assumed coverage on Ocular Therapeutix in a research note on Friday, February 9th. They set a “buy” rating and a $15.00 price target on the stock. One analyst has rated the stock with a sell rating and five have given a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $17.60.

Insider Transactions at Ocular Therapeutix

In other news, CFO Donald Notman sold 6,433 shares of the stock in a transaction that occurred on Wednesday, January 31st. The stock was sold at an average price of $4.95, for a total value of $31,843.35. Following the completion of the sale, the chief financial officer now directly owns 139,932 shares of the company’s stock, valued at $692,663.40. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In related news, CFO Donald Notman sold 6,433 shares of the stock in a transaction that occurred on Wednesday, January 31st. The stock was sold at an average price of $4.95, for a total transaction of $31,843.35. Following the completion of the sale, the chief financial officer now directly owns 139,932 shares of the company’s stock, valued at $692,663.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Rabia Gurses Ozden sold 7,764 shares of the stock in a transaction that occurred on Wednesday, January 31st. The shares were sold at an average price of $4.95, for a total value of $38,431.80. Following the sale, the insider now directly owns 92,767 shares of the company’s stock, valued at $459,196.65. The disclosure for this sale can be found here. Insiders sold a total of 39,366 shares of company stock valued at $194,862 over the last ninety days. 5.50% of the stock is currently owned by insiders.

Ocular Therapeutix Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.